FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 294:1421-1423 June 24, 1976 Number 26 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Treatment of transfusion-induced iron overload by daily intramuscular injection of the chelator desferrioxamine has not produced impressive urinary iron excretion. We attempted to augment net iron excretion by altering both the route and quantity of chelator administered. Two ascorbic acid-replete patients excreted a mean of 14.5 mg of iron per 24 hours after a single intramuscular injection of 750 mg of desferrioxamine. Excretion increased to a mean of 44.9 mg when this dose was delivered by a continuous 24-hour intravenous infusion. When the intravenous dose of chelator was increased incrementally to as high as 16,000 mg per 24 hours, iron excretion increased up to 180 mg per day. At these high-dose levels, efficiency of binding of iron to chelator was compromised. Constant exposure of the labile iron pool to a chelating agent markedly enhances net iron excretion in splenectomized transfusion-dependent patients.

This article has been cited by other articles:

• Bergeron, R. J., Wiegand, J., Brittenham, G. M. (2002). HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 99: 3019-3026 [Abstract] [Full Text]  
• Franchini, M., Gandini, G., de Gironcoli, M., Vassanelli, A., Borgna-Pignatti, C., Aprili, G. (2000). Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 95: 2776-2779 [Abstract] [Full Text]  
• Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., Harris, J. W. (1994). Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. NEJM 331: 567-573 [Abstract] [Full Text]  
• Schafer, A. I., Rabinowe, S., Le Boff, M. S., Bridges, K., Cheron, R. G., Dluhy, R. (1985). Long-term Efficacy of Deferoxamine Iron Chelation Therapy in Adults With Acquired Transfusional Iron Overload. Arch Intern Med 145: 1217-1221 [Abstract]  
• Robotham, J. L., Lietman, P. S. (1980). Acute Iron Poisoning: A Review. Arch Pediatr Adolesc Med 134: 875-879 [Abstract]  
• NIENHUIS, A. W., BENZ, E. J. Jr., PROPPER, R., CORASH, L., ANDERSON, W. F., HENRY, W., BORER, J. (1979). Thalassemia Major: Molecular and Clinical Aspects. ANN INTERN MED 91: 883-897 [Abstract]  
• Blume, K. G., Beutler, E., Chiller, R. K., Fahey, J. L., Sharkoff, D., Zia, P. K. (1978). Continuous Intravenous Deferoxamine Infusion: Treatment of Secondary Hemochromatosis in Adults. JAMA 239: 2149-2151 [Abstract]